II
CRSP icon

Inspire Investing’s CRISPR Therapeutics CRSP Stock Holding History

Inspire Investing’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$29 Hold
1
– – ﹤0.01% 1251
2026
Q1 		$25 Sell
1
-138
-99% -$7.28K ﹤0.01% 1091
2025
Q4 		$7.28K Buy
+139
New +$8.32K ﹤0.01% 939

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Inspire Investing's CRSP Position: Q2 2026 in Review

Inspire Investing held its CRISPR Therapeutics (CRSP) position steady in Q2 2026 at 1 share worth $29. The position accounts for ﹤0.01% of the portfolio, ranked #1251.

Inspire Investing first reported a position in CRSP in Q4 2025 and has held it in 3 quarters since. The position peaked at $7.28K in Q4 2025. 522 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Inspire Investing held 1 share of CRISPR Therapeutics worth $29 as of Q2 2026.
  • Inspire Investing left its CRISPR Therapeutics share count unchanged in Q2 2026.
  • CRISPR Therapeutics made up ﹤0.01% of Inspire Investing's portfolio in Q2 2026, its #1251 holding.
  • Inspire Investing first reported a position in CRISPR Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Inspire Investing's CRISPR Therapeutics position peaked at $7.28K in Q4 2025.
  • 522 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Inspire Investing's 13F filing for Q2 2026, filed 12 Aug 2026.